This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Burkitt lymphoma | |
|---|---|
| Name | Burkitt lymphoma |
| Field | Hematology, Oncology |
| Symptoms | Rapidly growing tumor, abdominal mass, jaw mass |
| Complications | Tumor lysis syndrome, bone marrow failure |
| Onset | Acute |
| Causes | Translocation of MYC gene, Epstein–Barr virus association |
| Diagnosis | Biopsy, immunophenotyping, cytogenetics |
| Differential | Diffuse large B-cell lymphoma, acute leukemia |
| Treatment | Intensive chemotherapy, rituximab, supportive care |
| Prognosis | Variable; high cure rates with modern therapy in children |
Burkitt lymphoma is a highly aggressive B-cell non-Hodgkin lymphoma characterized by very rapid tumor growth and frequent extranodal involvement. First described in epidemiological and clinical studies in mid-20th century Africa, it became central to discoveries linking viral oncogenesis, chromosomal translocations, and targeted therapy. Management typically involves intensive multiagent chemotherapy and supportive measures to prevent metabolic complications.
Patients often present with rapidly enlarging masses and systemic features. Common presentations include large jaw or facial tumors in regions historically associated with clinical reports from Uganda, abdominal masses causing bowel obstruction reported in case series from United Kingdom and United States, and extranodal lesions in organs cited in studies from France and Japan. Constitutional symptoms such as weight loss, night sweats, and fever are described in case reports involving institutions like Mayo Clinic and Memorial Sloan Kettering Cancer Center. Acute complications documented in clinical guidelines from European Society for Medical Oncology and National Cancer Institute include tumor lysis syndrome and marrow failure, sometimes necessitating care in centers like Johns Hopkins Hospital.
The defining molecular lesion involves translocation of the MYC oncogene to immunoglobulin loci, a mechanism elucidated in foundational cytogenetic work at National Institutes of Health. In endemic forms, strong association with Epstein–Barr virus infection was demonstrated in field studies by teams including researchers from Makerere University and London School of Hygiene and Tropical Medicine. Coincident factors such as chronic malaria exposure in regions studied by investigators from World Health Organization surveillance programs were implicated in immune modulation. Pathophysiology involves deregulated MYC-driven proliferation, supported by findings from laboratories at Cold Spring Harbor Laboratory and Harvard Medical School, with additional cooperating alterations reported by consortia including The Cancer Genome Atlas and researchers at Institut Pasteur.
Definitive diagnosis requires tissue biopsy with morphology and immunophenotype, as outlined in diagnostic protocols from World Health Organization and panels convened at International Agency for Research on Cancer. Immunohistochemistry typically shows markers characterized in textbooks from Oxford University Press and reviewed in position papers from American Society of Hematology. Cytogenetic demonstration of MYC translocation via techniques developed at Stanford University and confirmed by fluorescence in situ hybridization used in laboratories at Memorial Sloan Kettering Cancer Center is standard. Staging and imaging approaches drawing on guidelines from European Society for Medical Oncology and American College of Radiology include CT and PET scans with assessment practices from Mayo Clinic and Mount Sinai Health System.
Classification into clinical subtypes—endemic, sporadic, and immunodeficiency-associated—derives from epidemiologic descriptions by researchers at Makerere University, Oxford University, and studies from Centers for Disease Control and Prevention. Pathologic subclassification aligning with WHO schemas was developed by experts at International Agency for Research on Cancer and refined in consensus conferences involving faculty from University of Toronto and University of California, San Francisco. Molecular subgroups identified through sequencing efforts by The Cancer Genome Atlas and consortiums including investigators at Broad Institute highlight recurrent cooperating mutations cataloged in databases maintained by National Center for Biotechnology Information.
Standard care uses intensive, short-duration multiagent chemotherapy regimens pioneered in trials at St. Jude Children's Research Hospital and Dana-Farber Cancer Institute, often combined with anti-CD20 monoclonal antibody therapy developed by teams at Genentech and implemented globally. Supportive management to prevent tumor lysis syndrome follows protocols from American Society of Clinical Oncology and experience shared by Royal Marsden Hospital. In resource-limited settings, treatment adaptations informed by programs from Médecins Sans Frontières and collaborations with World Health Organization have been implemented. Hematopoietic stem cell transplantation has roles described in reviews from European Group for Blood and Marrow Transplantation.
Outcomes vary by stage, age, and access to care; pediatric series from St. Jude Children's Research Hospital and Dana-Farber Cancer Institute report high cure rates, whereas adult cohorts in registries compiled by Surveillance, Epidemiology, and End Results Program and institutions such as MD Anderson Cancer Center show lower survival. Prognostic factors identified in multi-institution analyses by International Prognostic Index investigators and studies from European Society for Medical Oncology include performance status and tumor burden. Long-term follow-up studies conducted at Memorial Sloan Kettering Cancer Center detail late effects and secondary malignancies.
Incidence patterns differ globally: endemic patterns in parts of Equatorial Africa and studies from Uganda contrast with sporadic cases documented across North America, Europe, and Asia in surveillance reports from World Health Organization and Centers for Disease Control and Prevention. Associations with Epstein–Barr virus prevalence and malaria transmission intensity were elucidated in epidemiologic fieldwork supported by Wellcome Trust and governmental agencies in the region. Population-based registries such as SEER Program and research networks including European Organisation for Research and Treatment of Cancer provide incidence and survival statistics.
Current research spans targeted therapeutics informed by genomic studies at Broad Institute and The Cancer Genome Atlas, immunotherapy strategies evaluated in trials at National Cancer Institute and Fred Hutchinson Cancer Center, and translational projects from Harvard Medical School and Cold Spring Harbor Laboratory. Key molecular themes investigated by consortia including International Cancer Genome Consortium involve MYC regulation, PI3K/AKT pathway interactions studied at Max Planck Institute for Biochemistry, and EBV latency mechanisms researched at Institut Pasteur. Collaborative clinical trials coordinated by networks such as Children's Oncology Group and European Society for Medical Oncology continue to refine risk-adapted approaches and novel agents.